Biology of chronic graft-

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

1. Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.International journal of hematology · 2024
   Trial
2. Identifying NOTCH signaling-specialized hematopoietic supportive subpopulation from mesenchymal stem cells.Stem cell research & therapy · 2026
   Article
3. Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?Journal of experimental & clinical cancer research : CR · 2025
   Review
4. Shared Biomarkers and Potential Mechanisms Between Hashimoto's Thyroiditis and Recurrent Miscarriage Revealed by Transcriptomics Analysis.International journal of general medicine · 2025
   Article
5. Every Fever Not Merely Due to Antibiotic Deficiency: Chronic Graft-Versus-Host Disease Case Report.Cureus · 2024
   Article
6. Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.Frontiers in immunology · 2024
   Review
7. CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice.Journal of neuroinflammation · 2023
   Article
8. Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms.Clinical kidney journal · 2023
   Article
9. Therapeutic Potential of a Senolytic Approach in a Murine Model of Chronic GVHD.Biology · 2023
   Article
10. Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
11. Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model.Blood advances · 2021
    Article
12. Mangiferin Promotes Bregs Level, Activates Nrf2 Antioxidant Signaling, and Inhibits Proinflammatory Cytokine Expression in Murine Splenic Mononuclear Cells In Vitro.Current medical science · 2021
    Article
13. Update on ocular graft-versus-host disease.Indian journal of ophthalmology · 2021
    Review
14. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2021
    Article
15. MicroRNAs in graft-versus-host disease: a review of the latest data.Bone marrow transplantation · 2020
    Review
16. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.Frontiers in immunology · 2020
    Review
17. Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients.Journal of cancer research and clinical oncology · 2019
    Article
18. The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study.Transfusion · 2019
    Article
19. Combination of pleuroparenchymal fibroelastosis with non-specific interstitial pneumonia and bronchiolitis obliterans as a complication of hematopoietic stem cell transplantation - Clues to a potential mechanism.Respiratory medicine case reports · 2019
    Article
20. [Safety and efficacy of ruxolitinib as a salvage regimen for patients with refractory acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as